Literature DB >> 24758546

High osteoprotegerin levels predict MACCE in STEMI patients, but are not associated with myocardial salvage.

Mette Bjerre1, Kim Munk, Astrid Drivsholm Sloth, Søren Steen Nielsen, Allan Flyvbjerg, Hans Erik Bøtker.   

Abstract

OBJECTIVES: High circulating levels of osteoprotegerin (OPG) carry prognostic impact in cohorts with various cardiovascular diagnoses. With the present study, we aim to investigate the role of OPG within the scale of myocardial damage.
DESIGN: This study includes 219 consecutive patients with acute ST-elevation myocardial infarction randomized to primary percutaneous coronary intervention (pPCI) or pPCI and remote ischemic per-conditioning. Salvage index via myocardial single-photon emission CT assessment (data available in 61% of the patients) was performed, and derived from Day 1 (myocardial area at risk) and Day 30 (final infarct size). Plasma OPG levels were measured using an in-house immunoassay. A combined end-point of all-mortality, myocardial infarction, stroke, readmission for heart failure and ischemic stroke/transient ischemic attack (Major Adverse Cardiac and Cerebrovascular Events [MACCE]) was used for follow-up; 45 (38-48 months).
RESULTS: High OPG levels were associated with the severity of cardiovascular disease. During follow-up, OPG was a predictor of MACCE (unadjusted, HR: 2.1, 95% CI: 1.14-3.85, P = 0.017). Adjustments for age, gender, and body mass index preserved the independent predictive power of OPG. However, OPG levels were neither associated with salvage index nor with the final infarct size. Remote ischemic per-conditioning had no effect on OPG levels.
CONCLUSION: Despite absent association between OPG levels and the scale of myocardial damage, high OPG levels predict a significantly increased risk of MACCE.

Entities:  

Keywords:  OPG; STEMI; myocardial salvage index

Mesh:

Substances:

Year:  2014        PMID: 24758546     DOI: 10.3109/14017431.2014.917767

Source DB:  PubMed          Journal:  Scand Cardiovasc J        ISSN: 1401-7431            Impact factor:   1.589


  4 in total

1.  Can Clinical and Functional Outcomes Be Improved with an Intelligent "Internet Plus"-Based Full Disease Cycle Remote Ischemic Conditioning Program in Acute ST-elevation Myocardial Infarction Patients Undergoing Percutaneous Coronary Intervention? Rationale and Design of the i-RIC Trial.

Authors:  Yu Zheng; Jan D Reinhardt; Jianan Li; Dayi Hu; Song Lin; Liansheng Wang; Ruozhu Dai; Zhiqing Fan; Rongjing Ding; Leilei Chen; Liang Yuan; Zhihui Xu; Yihui Cheng; Chengjie Yan; Xintong Zhang; Lu Wang; Xiu Zhang; Meiling Teng; Qiuyu Yu; Aimei Yin; Xiao Lu
Journal:  Cardiovasc Drugs Ther       Date:  2020-06-30       Impact factor: 3.727

2.  Osteoprotegerin levels in ST-elevation myocardial infarction: Temporal profile and association with myocardial injury and left ventricular function.

Authors:  Christian Shetelig; Shanmuganathan Limalanathan; Jan Eritsland; Pavel Hoffmann; Ingebjørg Seljeflot; Jon Michael Gran; Pål Aukrust; Thor Ueland; Geir Øystein Andersen
Journal:  PLoS One       Date:  2017-03-02       Impact factor: 3.240

Review 3.  The relevance of microRNA in post-infarction left ventricular remodelling and heart failure.

Authors:  Mieczysław Dutka; Rafał Bobiński; Jan Korbecki
Journal:  Heart Fail Rev       Date:  2019-07       Impact factor: 4.214

Review 4.  Osteoprotegerin and RANKL-RANK-OPG-TRAIL signalling axis in heart failure and other cardiovascular diseases.

Authors:  Mieczysław Dutka; Rafał Bobiński; Wojciech Wojakowski; Tomasz Francuz; Celina Pająk; Karolina Zimmer
Journal:  Heart Fail Rev       Date:  2021-07-27       Impact factor: 4.654

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.